NCT05218499 2026-03-02
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
Phase 2/3 Completed
Clinical Trials
9 trialsNCT03964233 2026-02-18
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Boehringer Ingelheim
Phase 1 Completed
NCT05372367 2026-02-03
A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor
Boehringer Ingelheim
Phase 1 Completed
NCT05512377 2026-01-21
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Boehringer Ingelheim
Phase 2 Completed
NCT06058793 2026-01-09
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
Phase 3 Completed
NCT03449381 2025-11-26
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Completed
NCT06084689 2025-09-02
EMPIRE
Institut Bergonié
Phase 2 Withdrawn
NCT05613036 2025-01-22
A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body
Boehringer Ingelheim
Phase 1 Completed
NCT06370871 2024-07-17
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
Boehringer Ingelheim
Phase 3 Withdrawn